RU2016115052A - Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение - Google Patents
Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение Download PDFInfo
- Publication number
- RU2016115052A RU2016115052A RU2016115052A RU2016115052A RU2016115052A RU 2016115052 A RU2016115052 A RU 2016115052A RU 2016115052 A RU2016115052 A RU 2016115052A RU 2016115052 A RU2016115052 A RU 2016115052A RU 2016115052 A RU2016115052 A RU 2016115052A
- Authority
- RU
- Russia
- Prior art keywords
- oligonucleotide
- paragraphs
- infection
- complex
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (42)
1. Олигонуклеотид, содержащий гуманизированный CpG-олигонуклеотид типа K и полидезоксиаденилат, причем полидезоксиаденилат размещен на 3’-стороне гуманизированного CpG-олигонуклеотида типа K.
2. Олигонуклеотид по п. 1, где гуманизированный CpG-олигонуклеотид типа K имеет длину не менее 10 нуклеотидов и состоит из нуклеотидной последовательности, представленной формулой:
где CpG-мотив в центре не метилирован, W представляет собой А или Т, и N1, N2, N3, N4, N5 и N6 могут представляет собой любые нуклеотиды.
3. Олигонуклеотид по п. 1 или 2, в котором гуманизированный CpG-олигонуклеотид типа K состоит из нуклеотидной последовательности, представленной в SEQ ID NO:1.
4. Олигонуклеотид по любому из пп. 1-3, в котором фосфодиэфирные связи в олигонуклеотиде частично или полностью заменены фосфоротиоатными связями.
5. Олигонуклеотид по п. 4, в котором фосфодиэфирные связи в олигонуклеотиде полностью заменены фосфоротиоатными связями.
6. Олигонуклеотид по любому из пп. 1-5, в котором полидезоксиаденилат имеет длину 20–60 нуклеотидов.
7. Комплекс, содержащий в олигонуклеотид по любому из пп. 1-6 и β-1,3-глюкан.
8. Комплекс по п. 7, в котором β-1,3-глюкан представляет собой лентинан, шизофиллан, склероглюкан, кулдлан, пакиман, грифолан или ламинаран.
9. Комплекс по п. 8, в котором β-1,3-глюкан представляет собой лентинан, шизофиллан или склероглюкан.
10. Комплекс, состоящий из олигонуклеотида, описанного в следующем (I), и β-1,3-глюкана, описанного в (II):
(I) олигонуклеотид, в котором полидезоксиаденилат длиной 20–60 нуклеотидов связан с 3’-концом олигонуклеотида, состоящего из нуклеотидной последовательности, представленной в SEQ ID NO: 1, и все фосфодиэфирные связи заменены фосфоротиоатными связями;
(II) лентинан или шизофиллан.
11. Комплекс по любому из пп. 7-10, обладающий структурой тройной спирали.
12. Комплекс по любому из пп. 7-11, обладающий активностью по активации В-клеток в отношении продуцирования IL-6 и активностью по активации дендритных клеток в отношении продуцирования IFN-α.
13. Фармацевтическая композиция, содержащая олигонуклеотид по любому из пп. 1-6 или комплекс по любому из пп. 7-12.
14. Фармацевтическая композиция по п. 13, которая предназначена для профилактики или лечения вирусной инфекции, злокачественного новообразования, аллергического заболевания или внутриклеточного паразитического простейшего или бактериальной инфекции.
15. Фармацевтическая композиция по п. 14, которая предназначена для профилактики или лечения вирусной инфекции.
16. Фармацевтическая композиция по п. 15, в котором вирусная инфекция представляет собой инфекцию РС-вируса или вируса гриппа.
17. Средство для стимулирования продуцирования интерферона типа I и/или II типа, включающее комплекс по любому из пп. 7-12.
18. Иммуностимулирующее средство, содержащее олигонуклеотид по любому из пп. 1-6 или комплекс по любому из пп. 7-12.
19. Иммуностимулирующее средство по п. 18, которое представляет собой вакцинный адъювант.
20. Профилактическое или терапевтическое средство от вирусной инфекции, злокачественного новообразования, аллергического заболевания или внутриклеточного паразитического простейшего или бактериальной инфекции, включающее олигонуклеотид по любому из пп. 1-6 или комплекс по любому из пп. 7-12.
21. Профилактическое или терапевтическое средство по п. 20, где вирусная инфекция представляет собой инфекцию РС-вируса или вируса гриппа.
22. Применение олигонуклеотида по любому из пп. 1-6 или комплекса по любому из пп. 7-12 для изготовления фармацевтической композиции.
23. Применение по п. 22, где фармацевтическая композиция представляет собой фармацевтическую композицию для профилактики или лечения вирусной инфекции, злокачественного новообразования, аллергического заболевания или внутриклеточного паразитического простейшего или бактериальной инфекции.
24. Применение по п. 23, где вирусная инфекция представляет собой инфекцию РС-вируса или вируса гриппа.
25. Способ лечения или профилактики заболевания у теплокровного животного, включающий введение фармакологически эффективного количества олигонуклеотида по любому из пп. 1-6 или комплекса по любому из пп. 7-12 теплокровному животному.
26. Способ по п. 25, где заболевание представляет собой вирусную инфекцию, злокачественное новообразование, аллергическое заболевание или внутриклеточное паразитическое простейшее или бактериальную инфекцию.
27. Способ по п. 26, где вирусная инфекция представляет собой инфекцию РС-вируса или вируса гриппа.
28. Способ по любому из пп. 25-27, где теплокровное животное представляет собой человека.
29. Способ индуцирования защитной иммунной реакции у теплокровного животного, включающий введение фармакологически эффективного количества олигонуклеотида по любому из пп. 1-6 или комплекса по любому из пп. 7-12 теплокровному животному.
30. Олигонуклеотид по любому из пп. 1-6, или комплекс по любому из пп. 7-12 для применения для лечения или профилактики вирусной инфекции, злокачественного новообразования, аллергического заболевания или внутриклеточного паразитического простейшего или бактериальной инфекции.
31. Олигонуклеотид или комплекс по п. 30, где вирусная инфекция представляет собой инфекцию РС-вируса или вируса гриппа.
32. Фармацевтическая композиция, содержащая (а) олигонуклеотид по любому из пп. 1-6 или комплекс по любому из пп. 7-12 и
(b) антиген.
33. Композиция по п. 32, которая предназначена для индуцирования иммунной реакции на антиген.
34. Композиция по п. 33, где антиген получен из патогенного микроорганизма.
35. Композиция по п. 34, которая предназначена для профилактики или лечения инфекции, вызванной патогеном.
36. Композиция по п. 35, где патоген представляет собой вирус.
37. Композиция по п. 36, где вирус представляет собой вирус гриппа или РС-вирус.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-196206 | 2013-09-20 | ||
JP2013196206 | 2013-09-20 | ||
PCT/JP2014/074835 WO2015041318A1 (ja) | 2013-09-20 | 2014-09-19 | 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020117033A Division RU2020117033A (ru) | 2013-09-20 | 2014-09-19 | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016115052A true RU2016115052A (ru) | 2017-10-25 |
RU2016115052A3 RU2016115052A3 (ru) | 2018-09-03 |
RU2723943C2 RU2723943C2 (ru) | 2020-06-18 |
Family
ID=52688965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020117033A RU2020117033A (ru) | 2013-09-20 | 2014-09-19 | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение |
RU2016115052A RU2723943C2 (ru) | 2013-09-20 | 2014-09-19 | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020117033A RU2020117033A (ru) | 2013-09-20 | 2014-09-19 | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение |
Country Status (18)
Country | Link |
---|---|
US (2) | US10202606B2 (ru) |
EP (3) | EP4253546A3 (ru) |
JP (4) | JP6525455B2 (ru) |
KR (2) | KR102400963B1 (ru) |
CN (3) | CN105683372A (ru) |
AU (2) | AU2014322046B2 (ru) |
BR (1) | BR112016005966B1 (ru) |
CA (1) | CA2923806C (ru) |
ES (2) | ES2960793T3 (ru) |
MX (2) | MX2016003668A (ru) |
MY (1) | MY178288A (ru) |
NZ (1) | NZ718900A (ru) |
PH (1) | PH12016500464B1 (ru) |
PL (1) | PL3048170T3 (ru) |
RU (2) | RU2020117033A (ru) |
SG (2) | SG10201802199TA (ru) |
TW (3) | TWI696630B (ru) |
WO (1) | WO2015041318A1 (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3103807B1 (en) * | 2014-02-06 | 2021-08-25 | Japan Science And Technology Agency | Peptide/ beta-1,3-glucan complex and production method therefor, and pharmaceutical composition containing peptide/ beta-1,3-glucan complex |
WO2016103531A1 (ja) * | 2014-12-26 | 2016-06-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 |
TW201639583A (zh) * | 2015-03-20 | 2016-11-16 | 國立研究開發法人醫藥基盤 健康 營養研究所 | 具有免疫賦活活性之含有CpG-間隔基-寡核苷酸複合體及其用途 |
JP6534146B2 (ja) * | 2015-06-10 | 2019-06-26 | 国立大学法人 東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
US10801026B2 (en) | 2015-10-15 | 2020-10-13 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
JP7128477B2 (ja) * | 2017-02-07 | 2022-08-31 | 京都府公立大学法人 | 病原性グラム陰性菌に対するワクチン |
WO2018180005A1 (ja) * | 2017-03-31 | 2018-10-04 | 国立研究開発法人日本医療研究開発機構 | コンドロイチン硫酸生合成を阻害するアンチセンス核酸 |
US20210003546A1 (en) * | 2018-03-09 | 2021-01-07 | Mandom Corporation | Method for detecting indicator of immune-related disease |
KR102191491B1 (ko) * | 2018-06-20 | 2020-12-15 | (주)큐젠바이오텍 | 베타글루칸-펩타이드 복합체 및 항생제를 포함하는 염증성 질환 예방 또는 치료용 약학적 조성물 |
CA3114149A1 (en) * | 2018-09-28 | 2020-04-02 | The University Of Kitakyushu | Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same |
KR102111039B1 (ko) * | 2018-10-30 | 2020-05-14 | 아주대학교산학협력단 | 항원특이적 면역반응 억제를 위한 커들란의 설하 투여용 조성물 |
CN114901824A (zh) | 2019-12-25 | 2022-08-12 | 日商那帕洁制药股份有限公司 | 连结有聚脱氧腺苷酸的短链含CpG的寡脱氧核苷酸、含有该寡脱氧核苷酸的复合体、及其用途 |
CA3201815A1 (en) | 2020-11-12 | 2022-05-19 | Daiichi Sankyo Company, Limited | Complex of .beta.-glucan and nucleic acid having controlled particle size |
CA3228856A1 (en) * | 2021-08-16 | 2023-02-23 | Peter C. Demuth | Compositions containing polynucleotide amphiphiles and methods of use thereof |
WO2023068104A1 (ja) * | 2021-10-20 | 2023-04-27 | 国立大学法人京都大学 | がん特異的細胞表面分子に対する結合性分子および光感受性分子の複合体ならびにアジュバントを含む医薬 |
WO2024084785A1 (ja) * | 2022-10-20 | 2024-04-25 | 一般財団法人阪大微生物病研究会 | Rsウイルスワクチンとしての利用に好適な組成物 |
CN116942808B (zh) * | 2023-07-21 | 2024-02-02 | 北京成大天和生物科技有限公司 | 一种重组带状疱疹疫苗组合物及其制备方法和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2001034207A1 (fr) | 1999-11-10 | 2001-05-17 | Japan Science And Technology Corporation | Supports de genes |
US8017742B2 (en) | 1999-11-10 | 2011-09-13 | Japan Science And Technology Agency | Gene carrier |
JP4057425B2 (ja) | 2001-03-13 | 2008-03-05 | 独立行政法人科学技術振興機構 | 多糖を利用する遺伝子キャリヤーとその製造方法 |
DE60221004T2 (de) * | 2001-05-21 | 2008-03-13 | Intercell Ag | Immunostimulierende oligodeoxyribonuklein moleküle |
JP2004107272A (ja) | 2002-09-19 | 2004-04-08 | Japan Science & Technology Corp | 遺伝子治療剤 |
WO2004100965A1 (ja) | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | 免疫刺激剤 |
KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
JP4712333B2 (ja) | 2004-08-31 | 2011-06-29 | 独立行政法人科学技術振興機構 | ハイブリッド多糖系キャリアーを用いる核酸類の導入方法。 |
JP2007070307A (ja) | 2005-09-09 | 2007-03-22 | Japan Science & Technology Agency | 免疫刺激性複合体 |
JP4878915B2 (ja) | 2006-05-25 | 2012-02-15 | 独立行政法人科学技術振興機構 | 核酸/多糖/カーボンナノチューブ複合体 |
JP2008100919A (ja) | 2006-10-17 | 2008-05-01 | Japan Science & Technology Agency | Th2細胞関連疾患の予防等に用いられる核酸/多糖複合体 |
US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
US8552165B2 (en) | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
PL2376107T3 (pl) | 2008-12-09 | 2014-09-30 | Coley Pharm Group Inc | Oligonukleotydy immunostymulujące |
JP5035808B2 (ja) | 2009-01-28 | 2012-09-26 | 公益財団法人北九州産業学術推進機構 | 三元複合体の製造方法 |
CN101745109A (zh) | 2010-02-01 | 2010-06-23 | 云南沃森生物技术股份有限公司 | 一种含CpG ODN和poly I:C佐剂的喷鼻型流感病毒疫苗制备方法 |
JP5884578B2 (ja) | 2012-03-16 | 2016-03-15 | 富士通株式会社 | アクセラレータ管理装置、アクセラレータ管理方法および入出力装置 |
CN202938106U (zh) | 2012-11-26 | 2013-05-15 | 甘俊辉 | 距离感应变光式led灯 |
-
2014
- 2014-09-19 AU AU2014322046A patent/AU2014322046B2/en active Active
- 2014-09-19 TW TW103132422A patent/TWI696630B/zh active
- 2014-09-19 TW TW112109803A patent/TW202332452A/zh unknown
- 2014-09-19 TW TW109118927A patent/TWI798557B/zh active
- 2014-09-19 JP JP2015537976A patent/JP6525455B2/ja active Active
- 2014-09-19 NZ NZ718900A patent/NZ718900A/en unknown
- 2014-09-19 EP EP23176351.7A patent/EP4253546A3/en active Pending
- 2014-09-19 PL PL14846493T patent/PL3048170T3/pl unknown
- 2014-09-19 BR BR112016005966-2A patent/BR112016005966B1/pt active IP Right Grant
- 2014-09-19 ES ES19182054T patent/ES2960793T3/es active Active
- 2014-09-19 WO PCT/JP2014/074835 patent/WO2015041318A1/ja active Application Filing
- 2014-09-19 CN CN201480051586.2A patent/CN105683372A/zh active Pending
- 2014-09-19 RU RU2020117033A patent/RU2020117033A/ru unknown
- 2014-09-19 SG SG10201802199TA patent/SG10201802199TA/en unknown
- 2014-09-19 MX MX2016003668A patent/MX2016003668A/es active IP Right Grant
- 2014-09-19 CN CN202210310954.7A patent/CN114762695A/zh active Pending
- 2014-09-19 US US15/022,856 patent/US10202606B2/en active Active
- 2014-09-19 CN CN202210311021.XA patent/CN114652739A/zh active Pending
- 2014-09-19 ES ES14846493T patent/ES2749627T3/es active Active
- 2014-09-19 RU RU2016115052A patent/RU2723943C2/ru active
- 2014-09-19 KR KR1020167009508A patent/KR102400963B1/ko active IP Right Grant
- 2014-09-19 KR KR1020227016729A patent/KR20220068276A/ko not_active Application Discontinuation
- 2014-09-19 SG SG11201601885WA patent/SG11201601885WA/en unknown
- 2014-09-19 EP EP14846493.6A patent/EP3048170B1/en active Active
- 2014-09-19 EP EP19182054.7A patent/EP3572511B1/en active Active
- 2014-09-19 MY MYPI2016700971A patent/MY178288A/en unknown
- 2014-09-19 CA CA2923806A patent/CA2923806C/en active Active
-
2016
- 2016-03-10 PH PH12016500464A patent/PH12016500464B1/en unknown
- 2016-03-18 MX MX2020012133A patent/MX2020012133A/es unknown
-
2018
- 2018-12-20 US US16/227,902 patent/US11015202B2/en active Active
-
2019
- 2019-05-02 JP JP2019087177A patent/JP6993649B2/ja active Active
-
2021
- 2021-04-16 AU AU2021202301A patent/AU2021202301B2/en active Active
- 2021-07-20 JP JP2021120059A patent/JP7278551B2/ja active Active
-
2023
- 2023-04-26 JP JP2023071978A patent/JP2023086856A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016115052A (ru) | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение | |
NZ718900A9 (en) | Complex containing oligonucleotide having immunopotentiating activity and use thereof | |
JP6308500B2 (ja) | 強化された免疫賦活化剤 | |
WO2009022215A8 (en) | Combination motif immune stimulatory oligonucleotides with improved activity | |
PH12017501233A1 (en) | Cyclic dinucleotides useful for the treament of inter alia cancer | |
JP2011250797A5 (ru) | ||
EA029939B8 (ru) | Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение | |
MX366858B (es) | Composicion farmaceutica que comprende un complejo de carga con portador polimerico y al menos y un antigeno proteinico o peptidico. | |
EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
TW200626720A (en) | Semi-soft C-Class immunostimulatory oligonucleotides | |
WO2008014979A3 (en) | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | |
TNSN06123A1 (en) | C-class oligonucleotide analogs with enhaced immunostimulatory potency | |
JP2016525102A5 (ru) | ||
WO2004098491A3 (en) | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES | |
JP2008000001A (ja) | 免疫刺激オリゴヌクレオチドおよびその医薬用途 | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
TW201639583A (zh) | 具有免疫賦活活性之含有CpG-間隔基-寡核苷酸複合體及其用途 | |
WO2004026260A3 (en) | Prophylactic and therapeutic hiv aptamers | |
CL2008002345A1 (es) | Compuesto derivado de quelidonina cuaternaria; procedimiento de preparacion; y su uso en la profilaxis o el tratamiento de una infeccion viral, cancer, disfuncion inmunologica, disfuncion metabolica y daño por radiacion. (divisional de la sol.552-04) | |
JP2015522266A5 (ru) | ||
ATE420658T1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
CA2519012C (en) | A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual | |
RU2016114713A (ru) | Способы и композиции для лечения s. equi инфекции | |
PH12018502320A1 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |